Manual of Lipidology Banshi Saboo, Sujoy Ghosh
INDEX
Page numbers followed by f refer to figure, fc refer to flowchart, and t refer to table.
A
Abetalipoproteinemia 39, 43, 123, 124t
Acquired immunodeficiency syndrome 214, 297
Acute coronary syndrome 84, 90, 163, 164, 182, 222
Acyl-CoA cholesterol acyl transferase 7
Adeno-associated virus 8 250
Adenosine triphosphate 7, 125, 164, 191
binding cassette
subfamily G member 85, 88
transporter 14, 82, 85, 88, 90, 125
Adipocyte triglyceride lipase 96, 199
Adiponectin 137
Advanced glycosylation end products 12
Advanced lipoprotein tests 123
Alanine aminotransferase 68, 156, 223, 232, 273
Alanine transaminase 301
Alirocumab 164
Alpha-linolenic acid 55
Alpha-tocopherol, beta-carotene cancer prevention study 57f59f
American Academy of Pediatrics 267
American Association of Clinical Endocrinologists 101, 102, 151, 162, 206, 213, 222
American College of Cardiology 117, 204, 212, 214, 219, 223, 225, 259, 263t
American College of Clinical Endocrinology Recommendations 163t
American College of Endocrinology 206
Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis 102
American Diabetes Association 205
Standards of Medical Care in Diabetes 102
American Heart Association 53, 54, 59, 117, 204, 212, 214, 219, 223, 225, 229, 259, 263t, 300
Amiodarone 192
Amlodipine 192
Anacetrapib 182
Angiopoietin-like protein 3 250
inhibitors 101, 164, 204
Anglo-Scandinavian Cardiac Outcomes Trial 217t
Ankle-brachial index 214
Antiretroviral protease inhibitors 118
Antiretroviral therapy 297, 298, 302
Antisense oligonucleotides 166, 185
mechanism of action of 34f
Antisense therapy 34
Apheresis 237
Apolipoproteins 4, 5, 132, 213
A1 77, 82, 90, 182, 184
transcriptional upregulators 183
B 11, 23, 163, 214, 222
particles 25f
synthesis inhibitor 164
C2 82
C3 82
inhibitors 101
functions of 5t
measurement of 132
types of 5t, 24
Arterial blood pressure lowering drugs study 157
Arterial disease, peripheral 161
Aspartate
aminotransferase 273
transaminase 301
Atazanavir 299
Atherogenesis 288f
Atherogenic diabetic dyslipidemia 198, 200, 207
Atheroma
complications 15
evolution 15
Atherosclerosis 11, 16, 18f, 20f, 21, 23, 24, 68, 69, 7476, 109, 288, 289f
coronary 176
mechanism of 11, 31f
multiethnic study of 215, 222
oxidation theory of 17
postprandial hypothesis of 18
response-to-retention hypothesis of 16f, 17
role in 24
initiation of 12
progression of 14
subclinical 64, 69
Atherosclerotic cardiovascular disease 27, 29, 73, 74, 78t, 87, 94, 100, 108, 136, 145, 161, 170, 173, 189, 200, 211, 214, 216, 219-221, 222t, 225, 246, 250, 263, 266, 287, 290, 292
development of 180
prevention of 108
risk 30, 32, 94, 231t
factors of 73
Atherosclerotic lesion formation 12fc
Atherosclerotic vascular disease 81, 91
Atherothrombosis, role in 15
Atorvastatin 137, 157, 192, 206, 218, 224, 232, 272
Autoimmune disorders 119
Autosomal recessive mutations 94
B
Basic lipidology 1
Bempedoic acid 164, 202
Beta-quantification 130
Bezafibrate Infarction Prevention study 172t, 203
Bile acid 202
sequestrants 164, 165, 195, 202
Blood
cholesterol, management of 291
lipids, abnormal 161
pressure 65, 273
systolic 216
Body mass index 68, 155, 229, 270, 273t, 300
Bromodomain 185
C
Canadian Cardiovascular Society 213, 214, 219, 225
Cancer 53, 223
Carbohydrates 54, 56, 58f, 148
types of 60f
Cardiovascular death 201, 228
Cardiovascular disease 8, 18, 23, 25f, 32, 53, 56, 59, 65, 81, 82, 89, 94, 103, 161, 170, 172, 182, 218t, 228, 259-261, 266, 278, 287, 290, 301
risk factors, prevalence of 279
therapies 162
Cardiovascular events 162, 170
Cardiovascular Health Integrated Lifestyle Diet-2 271f
Cardiovascular outcome trials 253
Cardiovascular risk 81
factors 211
reduction 162
Care lipid analysis, point of 132
Carotid intima medial thickness 68
Cerebrotendinous xanthomatosis 123
Cerebrovascular accident 216
Cerebrovascular disease 182
Cholestasis 222
severe 119
Cholesterol 38, 42, 86, 127, 148, 261, 279
absorption inhibitor 164
efflux capacity 69, 85f, 86
elevated 38
metabolism 7
remnant 94
rich lipoproteins 237
treatment trials 228
Cholesteryl esters 3, 4, 8, 13, 25, 66, 85
storage disease 39, 41, 122
transfer 181
protein 5, 19, 47, 66, 82, 84, 85, 90, 96, 125, 141, 167, 180, 181, 184, 185, 199, 250
Cholestyramine 164, 165
Chondroitin sulfate 25
Chronic inflammatory
disease 69
disorders 89
Chronic kidney disease 45, 73, 88, 118, 163, 194, 220, 222, 224, 224t, 230, 231, 259-263
grades of 260t
Chylomicronemia 123
Chylomicrons 3, 4, 17, 24, 146, 261
Citrate-dextrose 243
Clarithromycin 192
Clinical lipidology 51
Collaborative Atorvastatin Diabetes Study 201
Coronary artery calcium 292
score 221
Coronary artery disease 43, 66, 87, 111, 146, 156, 176, 183, 224, 287
Coronary revascularization 201
C-reactive protein 65
Creatine kinase 190, 273
Cushing's syndrome 118, 119
Cyclosporine 192
Cytochrome p450 16
Cytosolic lipid droplets 86
D
Dalcetrapib 182
Danazol 192
De novo synthesis 7
Dermatan sulfate 25
Desmosomal protein desmocollin-1 186
Dextran sulfate 239
liposorber 239
Diabetes mellitus 44, 45, 53, 73, 136, 163, 198, 219, 222, 225, 261
risk of development of 136
type 1 90, 205
type 2 8, 21, 82, 89, 94, 121f, 154, 166, 182, 198, 212, 216, 267
Diabetic dyslipidemia 198
management of 200, 204
Diacylglycerol acyltransferase 250
Dietary cholesterol 148, 271
Dietary fats 53, 55, 56, 59
guidance, evolution of 54
Dietary fibers 149
Diltiazem 192
Dimethylarginine, symmetric 88
Docosahexaenoic acid 99, 171, 176t, 203
Double filtration plasmapheresis 239
Drug
interaction 192, 302
therapy 200, 270, 272
Dysbetalipoproteinemia 94
familial 38, 42, 45, 119, 124
Dyslipidemias 37, 64, 74, 77, 78t, 115, 116, 161, 198, 211, 212, 226, 247t, 266, 270t, 271, 278, 297
atherogenic 64, 102fc, 212
drug treatment of 287
epidemiology of 299
management of 259, 299, 300
mixed 272
pathophysiology of 299
patterns of 70
severe 246
Dyslipoproteinemias, monogenic 47
E
Eicosapentaenoic acid 55, 99, 167, 171, 174, 176, 203
Electrophoresis 128
Endogenous lipid transport pathway 6
Endothelial cell 288, 289
Endothelial derived hyperpolarization factors 16
Endothelial lipase 82
Endothelial nitric oxide synthase 16, 88, 90
End-stage renal disease 224, 225
Enzyme 85
Epidermal growth factor-A 252
Erythromycin 192
Escherichia coli 252
Estimated glomerular filtration rate 172, 214, 224, 230
European Atherosclerosis Society 190, 213, 214, 219, 223, 225, 259
European Society of Cardiology 213, 214, 219, 223, 225, 259
Evacetrapib 182
Evolocumab 164
Exercise 150, 193
regimens 151
Exogenous lipid transport pathway 5
Extracellular matrix 12
Ezetimibe 158, 164, 195, 201
F
Familial chylomicronemia
score 42fc
syndrome 38, 41, 42
Familial hepatic lipase deficiency 38
Familial hypercholesterolemia, Simon Broome diagnostic criteria for 41t
Farsenoid X receptor 6
Fasting lipid-profile 271
Fasting plasma glucose 223
Fats 54
types of 60f
Fatty acids 5, 13, 54, 56, 56t, 96, 198, 199
monounsaturated 55, 57, 58, 59f, 148
nonesterified 95, 96, 198, 199
omega-3 polyunsaturated 158
polyunsaturated 53-56, 58, 60, 148
saturated 53, 56, 58, 58f, 60
short-chain 55
triglycerides consist of 95
Fatty liver 64, 68
index 69
Fatty streak 12
Fenofibrate Intervention and Event Lowering in Diabetes
study 166, 172
trial 171, 203
Fibrates 82, 98, 166, 171, 203
randomized control trials of 172t
role of 171
Fibrinogen 77
Fluvastatin 206, 224, 272
Foam cells, formation of 13, 14f
Food and Drug Administration 57, 171, 250, 282
approved statins 272t
Framingham Heart Study 81, 228
Fredrickson and Levy classification 38t
Free cholesterol 4
Free fatty acid 5, 19, 65, 66, 155, 199
Friedewald equation 130
G
Gemcabene 164
Gemfibrozil 192
Gene-silencing techniques 251
Genetic 30
lipoprotein disorders 45fc
polymorphisms 192
Glitazars 99, 203
Global burden of metabolic risk factors study 212
Glomerular filtration rate 260, 301
basis of 260t
Glomerulosclerosis, focal segmental 241
Glucagon like peptide-1 97
Glucose
lowering medications 97
transporter 4 137, 151
Glycosaminoglycan 16
Glycosylated hemoglobin 216, 223, 301
Glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1 125t
Greek Atorvastatin and Coronary Heart Disease Evaluation Study 157
H
Hashimoto's thyroiditis, chronic 119f
Heart
disease
chronic 31
congenital 195
coronary 26, 39, 42, 56, 57f-59f, 67, 161, 170, 172, 217, 299
ischemic 259
Outcomes Prevention Evaluation Trial 291
Protection Study 217
Helsinki Heart Study 172t
Hemodialysis 263
Heparin 239
sulfate proteoglycans 14
Hepatic effects 222
Hepatic lipase 43, 82, 96, 151, 199
deficiency 43, 124
Hepatitis 119, 222
Hepatocellular carcinoma 154
High-density lipoproteins 3-5, 8, 11, 14, 20, 58, 65, 66, 73, 74, 81, 85, 87, 88f, 90, 91, 96, 109, 127, 129, 145, 146, 161, 176, 180, 182, 182t, 185, 185t, 199, 239, 245, 259, 261, 263, 279, 301
cholesterol 23, 37, 39, 45, 55, 67, 72, 75, 77, 78, 81, 82, 84, 88, 90, 108, 110, 116, 122f, 125, 128, 155, 162, 163, 166, 172, 176, 180, 212-214, 216, 218-220, 222, 225, 234, 267, 269, 271
high levels of 47
low levels of 46
role of 109
elimination of 85f
function 87
infusions 182
metabolism, genetic disorders of 46
raising therapies, mechanism of action of 184f
role of 19
structural diversity 87
targeted therapeutics 181
trials of 185t
High-intensity statin 194, 232
therapy 206, 206t
High-low-density lipoproteins cholesterol 212
High-sensitivity C-reactive protein 74, 216, 231, 301
High-triglycerides 198
Hirsutism 119
Homocysteine 77
Homogeneous assays 129, 131
Hormone sensitive lipase 95, 96, 198, 199
Human immunodeficiency virus 214, 231, 297
infection 118
protease inhibitors 192
Human leukocyte antigen 192
Human lipoprotein metabolism 3
Human plasma lipoproteins 73, 73t, 74t
Hyperalphalipoproteinemia, familial 47
Hypercholesterolemia 38, 45fc, 48, 117, 241, 280
autosomal dominant 38, 40, 124, 246
autosomal recessive 38, 40, 124
familial 38–40, 121f, 122f, 124, 162, 202, 231, 237, 240, 266, 272, 280
heterozygous familial 40, 45, 163, 222
homozygous familial 40, 45, 250
prevalence of 212t
Hyperchylomicronemia 48
Hyperglycemia 76, 136, 199
Hyperinsulinemia 76
Hyperlipidemia 38, 49, 145
familial combined 39, 43, 45, 46, 94, 122f, 123, 124, 270
postprandial 17
Hypertension 73, 260
Hypertriglyceridemia 38, 42, 44, 45, 45fc, 76, 299
familial 43, 94, 125
isolated 44fc
moderate 101
polygenic causes of 43
severe 117, 118, 120, 171
Hypoalphalipoproteinemia
genetic forms of 46
primary 39, 46
Hypobetalipoproteinemia, familial 39, 44, 124
Hypothyroidism 118, 119, 194
primary 119f
I
Immunization 252
Immunoglobulin G 239
Indian Council of Medical Research-India Diabetes Study 212
Inflammatory diseases 231
Insulin
receptor substrate-1 137
resistance 64, 66
Intercellular adhesion molecule 13, 20
Intermediate-density lipoproteins 3, 4, 11, 25, 38, 66, 72-74, 95, 109, 129, 132, 146, 184, 199, 261
cholesterol 132
International Lipid Expert Panel 190
International Lipid Guidelines 228
Intima-media thickness 220
Intracellular adhesion molecule 288, 289
Intrauterine malnutrition 260t
Itraconazole 192
J
Japan EPA Lipid Intervention Study 173
K
Ketoconazole 192
Kidney disease 261, 262
chronic 45, 73, 88, 118, 163, 194, 220, 222, 224, 224t, 230, 231, 259-263
outcomes quality initiative 261
L
Lecithin-cholesterol acyltransferase 5, 8, 82, 85, 90, 125, 151, 184
deficiency 46, 120
Linoleic acid 56
Lipase maturation factor 1 125
Lipid 115, 145, 150, 279
direct adsorption of 239
disorders 39, 41, 42, 115
levels 267t
lowering
arm 217
drugs, effect of 154
therapy 245
management 234fc, 290
measurements and mathematical equations 109
oxidation product 17
role of 17
parameter 78
profile 115
abnormal 124t
research clinics-coronary primary prevention trial 165
Lipodystrophy 119
partial 120f
syndrome 298
Lipo-oxygenase controls collagen 17
Lipoproteins 11, 17, 21, 24, 45, 82, 145, 146, 214, 239, 288
A 4, 14, 20, 25, 29, 30f32f, 35, 7375, 109, 131
function 29
structure 29
role of 20
apheresis 237, 238, 241fc
associated phospholipase A2 77
atherogenic 237
classification of 129f, 261t
disorders
classification of 37
Fredrickson and Levy classification of 38t
hemoperfusion 239
isolated elevation of 241
laboratory assessment of 127
lipase 4, 12, 18, 44, 82, 92, 96, 118, 125, 198, 199, 250, 272
deficiency 38, 123
hydrolyzes 95
role of 19
metabolism 4, 6f, 9
disorders of 37
modification of 13
receptor related protein 5
residual 15
types of 24, 127
Liposorber system 238f, 239t
Liver
disease, chronic 119, 193
lipid disease of 154
X receptor 85, 86, 185
Lomitapide 164, 202
Lovastatin 192, 206, 218, 232, 272
Low-carbohydrate diet 150
Low-density lipoproteins 3-5, 11, 14-17, 25, 29, 39, 48, 65, 66, 73, 74, 78, 82, 85, 88, 94, 96, 102, 103, 109, 127, 129, 145, 146, 182, 184, 199, 204, 237-239, 245, 250, 261, 263, 301
apheresis 237
cholesterol 12, 23, 26, 39, 55, 72, 74, 77, 82, 84, 108, 110, 110f, 119f, 121f, 122f, 125, 130, 161-164, 194, 214, 217-219, 221, 222, 225, 231, 232, 234, 241, 245, 252, 267, 269, 271, 273, 287, 292, 294, 297, 300
raised 270
role of 16
receptor 14, 41, 85, 251
Low-dose statin 194
Low-high-density lipoproteins 95, 103
cholesterol 120f, 198
Low-intensity statin 232
Lymphocytes, T-regulatory 14
Lysosomal-acid lipase deficiency 41, 48, 122
M
Magnetic resonance spectroscopy 68
Major adverse cardiovascular events 95, 200, 228
Major cholesterol guidelines, comparative analysis of 211
Matrix metalloproteinases 15
regulation of 17
Medical Research Council 60
Mediterranean diet 149
Messenger ribonucleic acid 166
Metabolic adaptation 278
Metabolic syndrome 64, 65f, 65t, 216, 231, 298
atherothrombosis intervention in 100, 165, 173
Metalloproteinase-1, tissue inhibitor of 17
Microsomal transfer protein inhibitor 164
Microsomal triacylglycerol transfer protein 6
Microsomal triglyceride transfer protein 43, 202, 250
Mipomersen 26, 164, 166, 202
Moderate-intensity statin 232
therapy 206, 206t
Monoclonal antibodies 251, 252
Monocyte
chemoattractant protein-1 13, 20
chemotactic protein 288, 289
Monogenic lipid disorders 39
treatment of 48
Monogenic lipoprotein disorders 37, 44fc, 45fc
classification of 38t
Mononeuritis multiplex 123
Monounsaturated fat 271
Muscle
inflammation 190
weakness 190
Myalgia 190
Myocardial infarction 31, 73, 161, 171, 176, 191, 201, 211, 213t, 216, 217, 229, 260, 262
Myonecrosis 190
Myopathy 190
Myositis 190
N
National Cholesterol Education Program 54, 65, 132, 259
Adult Treatment Panel 204, 262
Recommendations 132
National Health and Nutrition Examination Surveys 127, 267
National Institute for Health and Clinical Excellence 259, 263
National Lipid Association 190, 263t
National Nutrition Monitoring Bureau 54, 56
National Obesity and Metabolic Syndrome Summit 229
Nefazodone 192
Nephelometry 31
Nephrotic syndrome 119
Neuromuscular disorders 193
Next-generation peroxisome proliferator-activated receptor agonists 167
Niacin 82, 100, 164, 165, 173, 203
Nicotinamide adenine dinucleotide phosphate oxidase and xanthine oxidase 16
Nicotinic acid 100, 164
Nitric oxide levels 16
Nonalcoholic fatty liver disease 9, 64, 68, 154, 223, 250
Noncommunicable diseases 53
Non-high-density lipoproteins 72
cholesterol 76, 108, 110f
Nonstatin therapy 294
Nuclear magnetic resonance 45, 87, 131
Nucleoside reverse transcriptase inhibitors 297
O
Obesity 21, 198
Omega-3 carboxylic acids 171
Omega-3 fatty acids 99, 149, 167, 170, 176, 176t, 203
Oral estrogens 200
Oxidized low-density lipoproteins 14, 15, 131
P
Pancreatitis, acute 117
Paraoxonase-1 88
Pediatric dyslipidemia 267
Percutaneous coronary intervention 230
Peripheral tissues 198
Peripheral vascular disease 182, 242
Peritoneal dialysis 263
Peroxisome proliferator-activated receptors 157, 166, 203, 282
Pharmacokinetics 253
Phospholipase domain containing 3 protein 68
Phospholipids 4, 5, 13
transfer protein 6, 82, 85
Phytoestrogens 150
Pitavastatin 206, 218, 272
Plant stanols 149
Plant sterols 148
Plasma
high-density lipoproteins cholesterol 81
lipoproteins 3, 72
properties of 4t
remnant lipoproteins 11, 17
Plasmat-futura 239
Plasmat-secura 239
Plasminogen
activator inhibitor 1 15, 65
structure 30f
Polyacrylate-coated polyacrylamide beads 239
Polyunsaturated fat 60f
Portfolio diet 150
Posaconazole 192
Pravastatin 206, 218, 224, 232, 272
Progressive inflammatory disease 69
Proprotein convertase subtilisin/kexin type 9 40, 164, 165, 201, 245
deficiency 44
inhibitors 195
targeted therapy 165
Protein 4, 148
kinase A 139
Proteoglycans 25
sub-endothelial 12
Psoriasis 231
R
Radial immunodiffusion 132
Radioimmunoassay 132
Randomized controlled trials 58f, 162, 191, 245, 268
Ranolazine 192
Refractory angina 242
Refsum's disease 242
Respiratory diseases, chronic 53
Retinoids 200
Reverse cholesterol transport 4, 8f, 85f, 86, 88, 180
pathway 7, 81
quantification of 86
Rhabdomyolysis 190
Rheumatoid arthritis 214, 231
Ribonucleic acid 87, 164
small-interfering 166, 251
Rosuvastatin 206, 218, 224, 232, 272
S
SAMS Clinical Index 190
Saturated fat 148
placement of 60f
Scavenger receptor
A1 14
B1 14, 82
Senile sensory-neural hearing loss 242
Serum amyloid A 88, 89
Simvastatin 192, 206, 218, 224, 232, 272
Single-nucleotide polymorphism 192
Single-spin density gradient ultracentrifugation 128
Sitosterolemia 38, 41, 124
diagnosis of 124
Skeletal muscle function 191
Small-dense low-density lipoproteins 131
cholesterol 76, 155
Small-molecule inhibitors 252
Smooth muscle cells 15
Sodium 148
glucose cotransporter-2 97
Sphingosine-1-phosphate receptors 88
Stanols 148
Statin 98, 156, 190, 200, 281
characteristics 192
diabetogenicity 136
induced diabetes, mechanism of 139fc
intensity of 232t
intolerance 189, 190
epidemiology of 191
mechanism of 191
pathogenesis of 191
rechallenge 194
safety 274
therapy 191, 217, 294
categorization of 294t
withdrawal 194
Stearoyl-CoA desaturase-1 inhibitors 159
Steatohepatitis, nonalcoholic 223
Sterols 149
regulatory-element-binding protein 7
Stroke 161, 201
Sulfonylureas 97
T
Tangier disease 39t, 46, 121
Telithromycin 192
Tendon xanthomas 122f
Therapeutic lifestyle change diet 147
dietary recommendations of 148t
Therapeutic lipidology 116, 143
Therapeutic plasma exchange 280
Thiazide diuretics 200
Thyroid
hormone receptor-beta 164t
stimulating hormone 123, 301
Torcetrapib 182
Total cardiovascular disease 213
Total cholesterol 23, 45, 58, 76-78, 127
Trans fatty acids 53, 55, 57, 58f, 147
Transaminitis 190
statin-associated 190
Triglycerides 3, 23, 25, 38, 39, 41, 42, 44, 45, 65-67, 82, 94, 96, 97, 102, 103, 109, 110, 110f, 122f, 127, 128, 145, 155, 162, 164, 166, 170, 172, 176, 199, 234, 239, 261, 267, 271, 272, 288, 300
elevated 94
lowering therapies 101, 204
management of 102fc
metabolism 95
rich lipoproteins 11, 17, 18, 66, 75, 96, 163, 199, 199f
metabolism 96f
remnants 18
role of 17
transfer of 181
Tuberous xanthomas 121f
Tumor necrosis factor 288f, 289f, 299
alpha 19, 65, 87
U
United Kingdom Prospective Diabetes Study 216
United States Food and Drug Administration 270
United States Preventive Services Task Force 212, 214f, 219t, 225t, 268
Unstable angina 73, 201
Uric acid 77
V
Vascular cell adhesion molecule 13, 20, 88, 288, 289
Vascular smooth muscle cells 14, 17, 86, 288, 289
Verapamil 192t
Very-low-density lipoproteins 3, 5, 11, 25, 38, 39, 41, 45, 65, 66, 72-74, 85, 96, 109, 127, 129, 146, 199, 155, 184, 198, 229, 261
cholesterol 82, 116, 139
remnants 66
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial 98, 171, 172, 203
Vitamin E 123
W
Wolman's disease 122
X
Xanthelasma palpebrarum 122f
×
Chapter Notes

Save Clear


_fm1Manual of LIPIDOLOGY_fm2
_fm3Manual of LIPIDOLOGY
Editors Sujoy Ghosh DM FRCP (London, Glasgow, Edinburgh) FACE FICP Professor Department of Endocrinology Institute of Post Graduate Medical Education and Research Kolkata, West Bengal, India Banshi Saboo MD PhD MNAMS (Diabetes) FRCP (UK) FACE Director and Chief Diabetologist Department of Diabetes Diabetes Care and Hormone Clinic Ahmedabad, Gujarat, India
_fm4
Jaypee Brothers Medical Publishers (P) Ltd
Headquarters
Jaypee Brothers Medical Publishers (P) Ltd
4838/24, Ansari Road, Daryaganj
New Delhi 110 002, India
Phone: +91-11-43574357
Fax: +91-11-43574314
Overseas Office
JP Medical Ltd
83 Victoria Street, London
SW1H 0HW (UK)
Phone: +44 20 3170 8910
Fax: +44 (0)20 3008 6180
© 2021, Jaypee Brothers Medical Publishers
The views and opinions expressed in this book are solely those of the original contributor(s)/author(s) and do not necessarily represent those of editor(s) of the book.
All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission in writing of the publishers.
All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.
Medical knowledge and practice change constantly. This book is designed to provide accurate, authoritative information about the subject matter in question. However, readers are advised to check the most current information available on procedures included and check information from the manufacturer of each product to be administered, to verify the recommended dose, formula, method and duration of administration, adverse effects and contraindications. It is the responsibility of the practitioner to take all appropriate safety precautions. Neither the publisher nor the author(s)/editor(s) assume any liability for any injury and/or damage to persons or property arising from or related to use of material in this book.
This book is sold on the understanding that the publisher is not engaged in providing professional medical services. If such advice or services are required, the services of a competent medical professional should be sought.
Every effort has been made where necessary to contact holders of copyright to obtain permission to reproduce copyright material. If any have been inadvertently overlooked, the publisher will be pleased to make the necessary arrangements at the first opportunity. The CD/DVD-ROM (if any) provided in the sealed envelope with this book is complimentary and free of cost. Not meant for sale.
Inquiries for bulk sales may be solicited at: jaypee@jaypeebrothers.com
Manual of Lipidology / Sujoy Ghosh, Banshi Saboo
First Edition: 2021
9789352700295
Printed at
_fm5Contributors
Editors
Associate Editors
Contributing Authors
_fm9Preface
Over the last two centuries, the role of lipids in the development of cardiovascular disease (CVD) has gained significant attention, and specifically, the role of cholesterol on the development of atherosclerosis. The first studies involving cholesterol and CVD way back to the early 1900s when Anichkov, a pathologist, provided rabbits with high cholesterol diets and observed stiffening of their artery walls. The first lipid lowering medication, niacin, was discovered coincidentally after it was tested on a rabbit schizophrenia model. One of the side effects observed was lowering of cholesterol. In the late 1970s, a Japanese microbiologist Akira Endo first discovered natural products with a potent inhibitory effect on cholesterol synthesis in a fermentation broth of Penicillium citrinum, during his search for antimicrobial agents. Concurrently, Brown and Goldstein (later earning the Nobel Prize for their work in 1985) demonstrated that HMG-CoA reductase inhibition represented the rate limiting step in cholesterol biosynthesis. These early basic and translational studies led to the production of statins. The first of many statin trials to come was the 4S study conducted in Scandinavian countries in the late 1980s and showed a significant reduction in CV events. Of note, many subsequent trials confirmed the benefits of statins in reducing risk of heart disease. On another front, the publication on the Mediterranean diet in the mid-90s transformed our understandings of the dietary components that protect against heart disease. In that study, participants randomized to olive oil, nuts survived longer following coronary bypass surgery than individuals kept on their regular diet. Several dietary studies have been conducted since confirming a distinct role for fats in the pathogenesis of heart disease.
Although the focus in treatment of lipid disorders is on reducing low-density lipoprotein (LDL) cholesterol concentrations, additional lipid-related independent risk factors, such as triglyceride (TG), high-density lipoprotein (HDL) cholesterol, and lipoprotein(a) levels should be used clinically to assess CV risk. Lipid treatment guidelines have continued to evolve as new evidence comes out from extensive research and clinical trials on lipid lowering medications. Clinicians need to be updated with all these emerging evidences when considering how to approach their patients with lipid disorders.
This book is published with the objective of providing both basic concepts and clinical approaches to understanding and managing lipid related disorders that is associated with an increased CV risk. To reach this aim, the focus is on up-to-date information on different aspects of lipidology. This has been possible through the contributions of endocrinologists and cardiologists who are expert in their respective _fm10fields. The book covers a wide range of topics from basic to clinic. The first section covers basic aspects of lipidology including genetics. Subsequent sections include updates from the recent clinical trials on lipid lowering medications, discussion on controversial areas in lipidology and current approaches in management. The last sections focus on management lipid disorders in special populations such as dyslipidemia in pregnancy, pediatric dyslipidemias, HIV induced dyslipidemia.
This book is intended for the postgraduate students, fellows, physicians, internists, cardiologists, endocrinologists, pediatricians and gynecologists with interest in lipids. The editors hope that by coupling of basic concepts and management approaches to lipid disorders, this book will assist the clinicians in making the best decisions in diagnosing and treating their patients. We have made every possible effort to maintain the quality and standard of “Manual of Lipidology”. Despite our best efforts, there may be some unintentional errors. Kindly excuse us for the same.
We also express our thanks to each and every manuscript contributors, our associate editors and industry. Finally, we express our thanks to the efficient staff of Jaypee Brothers Medical Publishers Ltd, who actively participated in this project.
We hope that this book lives up to the expectations of everyone.
Sujoy Ghosh
Banshi Saboo